Proton therapy

American Shared Hospital Services Reports 18% Period-over-Period Increase in Third Quarter 2022 Revenue to $4.8 Million

Retrieved on: 
Thursday, November 10, 2022
SAN, GLOBE, Review, Income, Trigeminal neuralgia, Marketing, NYSE, Leadership, PBRT, Proton therapy, U.S. Securities and Exchange Commission, HVS Global Hospitality Services, Orlando Health, Century, Annual general meeting, Radiosurgery, Leeds Gamma Knife Centre, Risk, Depreciation, Webcast, Loss, Malignancy, Annual report, CA, EBITDA, AMS, Contract, Pectus carinatum, Company, Home After Three Months Away, Nine Months, ASHS, GAAP, IGRT, Growth, Security (finance), VP, IMRT, CMS, COVID-19, Lithium, Video game, Health insurance, Pharmaceutical industry, Medical imaging, Bookkeeping, Bank

SAN FRANCISCO, CA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the third quarter and nine months of fiscal 2022, ended September 30, 2022.

Key Points: 
  • The gross margin percentage expanded 470 basis points to 40.5% of revenue compared to 35.8% for the third quarter of 2021.
  • Operating income for the third quarter of 2022 was $448,000 compared to operating income of $186,000 in the third quarter of 2021, an increase of 140.9%.
  • Adjusted EBITDA, a non-GAAP financial measure, was $1,999,000 for the third quarter of 2022, compared to $1,562,000 for the third quarter of 2021, an increase of 28.0%.
  • Cash at September 30, 2022 was $11,664,000, an increase of $3,401,000 from the December 31, 2021 balance of $8,263,000.

Insights on the Proton Therapy Global Market to 2027 - Technological Advancement in Therapeutic Systems of Cancer Treatment Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 10, 2022
Health, Oncology, Proton, Customer support, Proton therapy, Business Growth Fund, Investment, Economic development, Use, Strategic management, R, Market share analysis, Value, Decision-making, Growth, Acquisition, COVID-19, CAGR, Certification, Pharmaceutical industry, Fine chemical, Medical imaging, Retail

The Global Proton Therapy Market is projected to grow with a significant CAGR in the forecast period.

Key Points: 
  • The Global Proton Therapy Market is projected to grow with a significant CAGR in the forecast period.
  • Besides, the qualitative and quantitative parameters provided in the report with detailed analysis highlights the driving and restraining factors of the Global Proton Therapy Market.
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Proton Therapy Market during the forecast period?
  • What modes and strategic moves are considered suitable for entering the Global Proton Therapy Market?

Insights on the Proton Therapy Global Market to 2031 - by Indication, Product Type, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 10, 2022
General Health, Health, Oncology, Proton, Quality of life, Proton therapy, Prevalence, Investment, Adoption, Tissue, Technology, Cancer, Wilms' tumor, Patient, Awareness, Growth, Radiation, CAGR, Medical imaging

The global proton therapy market was valued at $438.33 million in 2021, and is projected to reach $1579.39 million by 2031, registering a CAGR of 13.65% from 2022 to 2031.

Key Points: 
  • The global proton therapy market was valued at $438.33 million in 2021, and is projected to reach $1579.39 million by 2031, registering a CAGR of 13.65% from 2022 to 2031.
  • Proton therapy is the most precise and advanced type of radiation therapy.
  • Moreover, patients are eager to know more about proton therapy treatment process and increase in recognition of proton therapy drive growth of the market, globally.
  • Moreover, introduction of proton therapy in emerging economies is expected to offer lucrative growth opportunities for key players in the market.

American Shared Hospital Services Announces Third Quarter 2022 Earnings Conference Call

Retrieved on: 
Thursday, November 3, 2022
Proton therapy, Company, CA, Pectus carinatum, Call, GLOBE, Trigeminal neuralgia, NYSE, IGRT, Pain scale, IMRT, AMS, Radiosurgery, Malignancy, Medical imaging, Conference

SAN FRANCISCO, CA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its third quarter 2022 financial results on Thursday November 10th, 2022 at 3:00 pm ET / 12:00 pm PT. The third quarter 2022 financial results press release will be issued before the market open on Thursday, November 10, 2022.

Key Points: 
  • Conference Call on Thursday November 10th, 2022 at 3:00 pm ET / 12:00 pm PT
    SAN FRANCISCO, CA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced that the Company will hold a quarterly conference call to discuss its third quarter 2022 financial results on Thursday November 10th, 2022 at 3:00 pm ET / 12:00 pm PT.
  • The third quarter 2022 financial results press release will be issued before the market open on Thursday, November 10, 2022.
  • To participate, please call 1 (844) 413-3972 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call.
  • About American Shared Hospital Services (NYSE American: AMS)
    American Shared Hospital Services is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services.

Asia Pacific Proton Therapy Market Report 2022: Development of FLASH Radiation Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, November 4, 2022
Surgery, Medical Devices, Hospitals, Health Technology, Biotechnology, Radiology, Managed Care, Health, Oncology, Proton, Product type, Proton therapy, Toshiba, Hitachi, Sumitomo Corporation, CAGR, Government, Radiation, Indiana University Health Proton Therapy Center, Image, Siemens, FLASH, Breast cancer, Prevalence, Conditional sentence, Prostate cancer, Person, Country, Cancer, End user, Medical imaging, Others, Hospital

A method called FLASH radiation, which uses extremely high dose rates for photon and proton treatments, is currently being developed.

Key Points: 
  • A method called FLASH radiation, which uses extremely high dose rates for photon and proton treatments, is currently being developed.
  • Additionally, the development and approval of products for proton therapy may benefit market growth in advanced countries like Japan.
  • The China market dominated the Asia Pacific Proton Therapy Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $74,530.9 Thousands by 2028.
  • Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3

Retrieved on: 
Wednesday, November 2, 2022
Proton, MD, Paris-Saclay University, SEC, GLOBE, COVID-19, Cancer research, Institute, Department, Head, Private Securities Litigation Reform Act, Company, Associate, EIB, Chapel Hill, Radiation therapy, Radiation, Stanford University, Service, University, UPMC Hillman Cancer Center, Lausanne University Hospital, Patient, Cancer, Hillman, Risk, Immunology, AMF, Memorial Sloan Kettering Cancer Center, Curie Institute (Paris), Drug development, UPMC, Annual report, Weill Cornell Medicine, Interventional radiology, NBTXR3, Education, Forward-looking statement, Proton therapy, Pharmaceutical industry, Medicine, Audit, Hospital, Medical imaging, Euronext, Oncology, Medicine, Nanobiotix, Otorhinolaryngology

As such, our scientific advisory board brings diverse, world class expertise across the fundamental disciplines responsible for decision-making in oncology.

Key Points: 
  • As such, our scientific advisory board brings diverse, world class expertise across the fundamental disciplines responsible for decision-making in oncology.
  • For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter .
  • This press release contains certain forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995.
  • Such forward-looking statements are made in light of information currently available to us and based on assumptions that Nanobiotix considers to be reasonable.

United States Proton Therapy Market Report 2022 to 2027: Featuring IBA Proton Therapy, Varian Medical Systems and Elekta - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 26, 2022
Biotechnology, Health, Oncology, Proton, Proton therapy, Radiation, Radiation exposure, Patient, Industry, US, Growth, COVID-19, Neoplasm, Cancer, Algorithm, Medical imaging, Pharmaceutical industry

The United States Proton Therapy Market is expected to reach US$ 1.8 Billion by 2027.

Key Points: 
  • The United States Proton Therapy Market is expected to reach US$ 1.8 Billion by 2027.
  • Besides, for children, those most vulnerable and susceptive to the damage of conventional radiation therapy, proton therapy offers less radiation exposure while demoting side effects.
  • COVID-19 Impact on United States Proton Therapy Industry:
    Despite the outbreak of COVID-19 worldwide, the proton therapy market has increased at a constant speed.
  • As per the analysis, United States Proton Therapy Market Size was US$ 1.1 Billion post-pandemic recoveries in 2021.

Mevion Selected to Provide Proton Therapy Technology to the Froedtert & the Medical College of Wisconsin Health Network

Retrieved on: 
Tuesday, October 25, 2022
Technology, General Health, Health, Other Technology, Physician, Froedtert Hospital, LinkedIn, Frazier Healthcare Partners, National Comprehensive Cancer Network, Froedtert Health, Neoplasm, Science, Education, Proton therapy, Patient, Medical College of Wisconsin, PBS, Hospital, Multimedia, Medical college, Partnership, Varian Medical Systems, Cancer, Technology, MD, Scan (company), Doctor of Philosophy, Health, Department, Radiation therapy, Adult, MCW, Medical imaging, Proton

Mevion Medical Systems is pleased to announce it has entered into a contract with the Froedtert & the Medical College of Wisconsin health network to bring the MEVION S250i Proton Therapy System to Wisconsin.

Key Points: 
  • Mevion Medical Systems is pleased to announce it has entered into a contract with the Froedtert & the Medical College of Wisconsin health network to bring the MEVION S250i Proton Therapy System to Wisconsin.
  • Through its Cancer Network, the Froedtert & MCW health network will offer adults treatment with the MEVION S250i system and will work with Childrens Wisconsin, one of the nations top pediatric facilities, to treat pediatric patients with proton therapy.
  • "We are excited to partner with the Froedtert & the Medical College of Wisconsin health network to bring proton therapy to Wisconsin," said Tina Yu, PhD, chief executive officer and president of Mevion.
  • Connect with us on LinkedIn: Mevion Medical Systems
    The Froedtert & the Medical College of Wisconsin regional health network is a partnership between Froedtert Health and the Medical College of Wisconsin, supporting a shared mission of patient care, innovation, medical research and education.

Mevion Identifies Site for New Compact Proton Therapy System in Development

Retrieved on: 
Sunday, October 23, 2022
Research, Medical Devices, Other Health, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Adoption, LinkedIn, Risk, Science, Proton therapy, LINAC, Patient, PBS, Multimedia, Varian Medical Systems, Cancer, Secondary malignant neoplasm, Stanford University Medical Center, Scan (company), CEO, Radiation, Medical imaging, Proton

Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that it is developing the MEVION S250-FIT Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS).

Key Points: 
  • Mevion Medical Systems, the leading provider of compact proton therapy systems for use in radiation treatment for cancer patients, announced today that it is developing the MEVION S250-FIT Proton Therapy System with HYPERSCAN Pencil Beam Scanning (PBS).
  • Historically, the size, cost, and inherent complexity of proton technologies have limited the adoption of proton therapy.
  • Since 2004, Mevion Medical Systems has been the leading provider of compact proton therapy systems for cancer care.
  • Dedicated to advancing the design and accessibility of proton therapy worldwide, Mevion was the first company to innovate this new single-room platform and continues to further the science and application of proton therapy.

NJ Doctors: Katie Couric Shares Important Message About Breast Cancer Screenings

Retrieved on: 
Wednesday, October 26, 2022
Proton, Lung, American Cancer Society, Disease, Head, Woman, Diagnosis, Freedom, Neck, Proton therapy, Patient, Procurement, Sarcoma, Breast cancer, Awareness, Cancer, Katie Couric, Prostate, Breast, Today, Survival, Radiation, Brain, NBC, Heart, Breast Cancer Awareness Month, Medical imaging

SOMERSET, N.J., Oct. 26, 2022 /PRNewswire/ -- The doctors at ProCure Proton Therapy Center applaud TV personality Katie Couric for bringing more attention to the importance of annual mammograms as a life-saving tool against breast cancer.

Key Points: 
  • SOMERSET, N.J., Oct. 26, 2022 /PRNewswire/ -- The doctors at ProCure Proton Therapy Center applaud TV personality Katie Couric for bringing more attention to the importance of annual mammograms as a life-saving tool against breast cancer.
  • Couric, the former host of NBC's "Today Show," was diagnosed in June after falling behind on her annual mammogram.
  • After undergoing surgery in July and radiation treatment in September, Couric shared her story to raise awareness during Breast Cancer Awareness Month in October.
  • The 5-year survival rate for breast cancer detected before it spreads is 99 percent, according to the American Cancer Society.